about
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.New agents within the preoperative chemotherapy of non-small cell lung cancer.A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer.Cancer clinical trials in Central and Eastern Europe: historical review.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.Cancer-related anemia: pathogenesis, prevalence and treatment.The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursErlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland.Crizotinib in the treatment of non-small-cell lung carcinoma.Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.Analysis of treatment results in primary germ cell tumours with mediastinal location: own experience.A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the EuropeaDocetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
P50
Q27851683-89502B68-405A-47FF-933D-ECE7B9BAD617Q33327988-80A1E64A-E73A-4951-9D31-403BA1F422C6Q33340256-4DB74F67-B620-4EF6-BC1D-9189A4618B59Q33348693-F37ED68A-0F3E-4730-8009-F9159E20255EQ33371137-544425A0-923A-425A-9249-BD3B75DEA6D8Q33388979-76C9ACAE-D105-4851-A9D5-B3D5DD544240Q33751194-3AAE7BC3-11CB-42A1-A9E1-6A9BF456CAB8Q33796176-2437141D-C1F0-4D85-BACB-0BE5B25957A5Q34231171-B1D90FB3-4E12-4698-A262-B3B8D99CF296Q34447482-BCE4B78A-56BF-45F7-B87B-BE7C966DC74CQ34474598-3EA66348-1B65-4ACC-A405-F11718155CB7Q34491507-8EFB0970-A77E-4072-9EAD-3F0B03A69AD0Q34551456-13D9AB95-0906-47F0-8772-3F13B212ED41Q34630161-104EA6D4-5D7E-4BD1-9C6D-776718CD7CAEQ34635822-9A2C7B36-9C25-483A-A81F-076A2A271013Q34658812-48B47895-281D-4499-A81C-59C3506D996EQ34809526-BC13CFA2-7965-4502-B96C-63CA52B4E60CQ35010777-BE88A782-8FF5-473D-9C25-47759F5D6D7DQ36108556-D0DD9186-956C-4844-B3B1-15973B1CA210Q36378565-10342F83-1FD1-4F91-AFA6-DD9841DBBC6EQ36387910-31E74408-1E0E-4617-BBA9-D35709BC738CQ36942514-455F7C3A-EEE9-44AE-9D76-0F83B4D5F9A8Q36942691-456FC89C-6F93-4A5B-A065-C88FC7A84D64Q37539257-01B784E0-5429-45B1-B74A-864E1D7D6C8CQ37659109-BA52B4EF-BA28-42E3-A515-697DD41A07DBQ37937339-77232DB6-0ECF-43FB-80D1-43A8DA2637F0Q38194931-BEFD9869-604A-4DED-9DF1-B3AACC17F813Q39428802-5B28BCBB-C24B-466B-A52C-2D0154B5DEE0Q42596227-049A60F2-4392-4B58-B90B-E58B12E2F148Q42673292-21C76947-6F70-42AD-A1C2-1840E9B8B844Q42997441-EE0F4E8F-3ED8-4D59-8B91-28829A02C87FQ43075589-343338AB-45C8-4CD1-A733-AB528DCDA205Q43138109-DD0EA2D1-60A4-46B1-9E2B-5CCFBB2AB84AQ43143884-5F955A0B-A21A-4A27-8C27-3CD2B5B2D8D4Q43274035-C3C91695-3506-4F8F-BBFD-47EFF768E160Q43775249-49F9F109-A044-4432-951F-3FF93BC21594Q43955289-032AD4FC-312E-4121-9F8B-7054BC440A72Q44216643-8B4C1A09-F4AF-4FFB-9E29-B3F1E59BA73AQ44362096-69C3C4CA-3617-4C69-8B8E-DD76EF825048Q44547450-FD73B445-C394-48F8-AFA7-2A0F0A8053A4
P50
description
Polish oncologist and researcher
@en
Pools onderzoeker
@nl
cercetător polonez
@ro
chercheur polonais
@fr
investigador polaco
@es
investigador polaco
@gl
investigador polonès
@ca
polnischer Forscher
@de
polski lekarz onkolog
@pl
ricercatore polacco
@it
name
Maciej Krzakowski
@ast
Maciej Krzakowski
@ca
Maciej Krzakowski
@de
Maciej Krzakowski
@en
Maciej Krzakowski
@es
Maciej Krzakowski
@fr
Maciej Krzakowski
@ga
Maciej Krzakowski
@gl
Maciej Krzakowski
@it
Maciej Krzakowski
@nl
type
label
Maciej Krzakowski
@ast
Maciej Krzakowski
@ca
Maciej Krzakowski
@de
Maciej Krzakowski
@en
Maciej Krzakowski
@es
Maciej Krzakowski
@fr
Maciej Krzakowski
@ga
Maciej Krzakowski
@gl
Maciej Krzakowski
@it
Maciej Krzakowski
@nl
prefLabel
Maciej Krzakowski
@ast
Maciej Krzakowski
@ca
Maciej Krzakowski
@de
Maciej Krzakowski
@en
Maciej Krzakowski
@es
Maciej Krzakowski
@fr
Maciej Krzakowski
@ga
Maciej Krzakowski
@gl
Maciej Krzakowski
@it
Maciej Krzakowski
@nl
P214
P101
P106
P1412
P1559
Maciej Krzakowski
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-3324-0900
P735
P7859
viaf-101640733